logo
Greater Boston's median single-family home price hits $1M

Greater Boston's median single-family home price hits $1M

Axios21-07-2025
Greater Boston's housing market reached new heights last month, with the median price for a single-family home topping $1 million.
Why it matters: The higher home prices climb, the less feasible homeownership becomes for Boston-area residents, housing advocates say.
That problem is likely to worsen as Massachusetts fails to expand housing production — and with it, affordable housing options — to meet demand.
Catch up quick: The Greater Boston Association of Realtors announced last week that the local housing market reached the $1 million milestone in June.
"If you needed any more evidence that Greater Boston was one of the most desirable areas of the country to live, you just got it," Mark Triglione, president of the association, said in a news release.
The median price for a condo was $725,000 in June, down 3.3% from May and the previous year.
Zoom in: Median single-family home prices had been ticking toward seven digits since April, even as more homes stayed on the market longer, per the GBAR.
Some homebuyers believed they'd see prices drop as a result, "but the data and buying behavior continues to defy that notion," Triglione said.
Reality check: A family would need a down payment of $200,000 to buy a home without paying extra for private mortgage insurance, and that doesn't take into account the extra costs tacked on, including closing costs, HOA fees, utility bills and expenses for repairs.
For many Boston-area residents, that price is out of reach. The city's median household income in 2023 was $94,755, per census data.
Meanwhile, half of tenants spend more than 30% of their monthly income on rent (one-fourth spend more than half).
What they're saying: That $1 million mark suggests that "Boston is no longer for the people we serve," Symone Crawford, executive director of the Massachusetts Affordable Homeownership Alliance, tells Axios.
"We're being pushed out."
Other housing advocates point to the increase in corporations buying homes and a lack of foreclosure protections and other homeowner and rental protections as factors driving housing costs — in addition to the supply crunch.
A 2023 Metropolitan Area Planning Council report shows 21% of residential properties sold between 2004 and 2018 were bought by an investor.
Homes for All Massachusetts, City Life/Vida Urbana and other groups are working with community land trusts to buy more homes to make them permanently affordable, says Carolyn Chou, Homes for All Massachusetts' executive director.
The other side: Dino Confalone, a real estate agent with Gibson Sotheby's International Realty, says it all comes down to supply.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Yahoo

time2 hours ago

  • Yahoo

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus Bain Capital leads $300 million financing commitment PRINCETON, N.J. & BOSTON, July 28, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, "BMS") and Bain Capital today announced the creation of a new independent biopharmaceutical company ("NewCo") focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital. The NewCo has a broad pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that each target promising mechanisms in autoimmune diseases. The most advanced assets in the NewCo's portfolio are afimetoran, an oral, potential best-in-class TLR7/8 inhibitor that is currently being studied in a Phase 2 clinical trial for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor, which successfully established proof-of-concept in a positive plaque psoriasis Phase 2 trial. Other licensed assets include BMS-986326, a novel, potential best-in-class, IL2 fusion protein that is currently being studied in Phase 1 clinical trials for SLE and atopic dermatitis, and BMS-986481 and BMS-986498, two Phase 1-ready biologics targeting the IL18 and IL10 pathways respectively. The assets licensed to NewCo reflect the strength of BMS's scientific innovation and hold promise to address unmet needs for patients with autoimmune diseases. As part of the agreement, BMS will retain a nearly 20 percent equity stake in NewCo and will be entitled to royalties and milestones tied to the success of each asset. Robert Plenge, MD, PhD, Executive Vice President and Chief Research Officer at BMS, will also serve on NewCo's Board of Directors. This transaction reflects BMS's strategic shift in Immunology research to focus on assets that have the potential to reset the immune system and promote tissue repair. It also further demonstrates the company's sharpened strategy to invest in areas where BMS is best positioned to lead, while enabling the continued development of promising medicines. "These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients," said Julie Rozenblyum, Senior Vice President, Business Development at BMS. "Bain Capital's exceptional track record in building successful life science companies by providing focused development and dedicated resources makes them ideally suited to advance these assets to realize their full promise." Daniel S. Lynch will serve as the Executive Chairman of the Company's Board of Directors and interim CEO. Mr. Lynch is an accomplished biopharmaceutical industry leader with decades of strategic, management and operational experience at companies spanning many stages of growth. Nicholas Downing, MD, Adam M. Koppel, MD, PhD, and Andrew Kaplan from Bain Capital will also join Mr. Lynch and Dr. Plenge of BMS on NewCo's Board of Directors. "We are excited to partner with BMS and we share their commitment to improving lives through science," said Adam Koppel, a Partner at Bain Capital Life Sciences. "We look forward to working together and leveraging our company creation experience to build out this new platform and advance these distinct assets in an effort to bring innovative, high-quality therapies to patients with autoimmune diseases." "This is a unique opportunity to build an innovative biotech company with a strong scientific foundation and differentiated development capabilities," said Mr. Lynch. "I'm thrilled to have the opportunity to leverage my background and experience to contribute to the success of the company as it seeks to develop much-needed new therapies, and I look forward to supporting BMS and Bain Capital in the build-out of the company's operations." Bain Capital is investing in NewCo through its Life Sciences and Private Equity teams, drawing on over 40 years of supporting the growth and innovation of healthcare companies globally. Canada Pension Plan Investment Board also joined the investment. About Bristol Myers Squibb: Transforming Patients' Lives Through ScienceAt Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at and follow us on LinkedIn, X, YouTube, Facebook and Instagram. Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products, the creation of NewCo and the agreement with NewCo. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to, the creation of NewCo and the agreement with NewCo may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated, that the assets described in this press release, may not achieve their primary study endpoints or receive regulatory approval for the indications described in this release in the currently anticipated timeline or at all and, if approved, whether such assets will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. About Bain CapitalFounded in 1984, Bain Capital is one of the world's leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit Follow @BainCapital on LinkedIn and X (Twitter). corporatefinancial-news View source version on Contacts Bristol Myers Squibb Media Inquiries: media@ Investors: Bain Capital Scott Lessne / Charlyn LuskStantonslessne@ / clusk@ (646) 502-3569 / (646) 502-3549 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Biologic Therapeutics Market to Hit $794.5 Billion by 2029
Biologic Therapeutics Market to Hit $794.5 Billion by 2029

Yahoo

time8 hours ago

  • Yahoo

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative Vaccines" BOSTON, July 28, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected to increase from $499.2 billion in 2024 to reach $794.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029. This report provides a comprehensive analysis of the global market for biologic therapeutic drugs, segmented by product type (such as mAbs vaccines, and cell and gene therapies), source (mammalian, microbial, others), application (oncology, autoimmune, and infectious diseases), and region (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). It explores key market trends, challenges, and ESG developments, and examines the emerging technologies shaping the industry. The report also includes a competitive landscape analysis with market share rankings and detailed profiles of leading companies. This report is particularly relevant now due to the growing demand for innovative therapies and the rapid advances in regenerative medicine. Increased investments and intensified research activities are accelerating the development of biologic drugs, while a surge in product approvals is expanding treatment options in many medical fields. These factors are collectively driving significant growth in the biologics market, making timely insights into trends, challenges, and competitive dynamics more critical than ever. The factors driving the market's growth include: Growing Demand for Biologics: Biologics are increasingly favored due to their high efficacy, targeted action, and ability to treat complex diseases like cancer and autoimmune disorders. Patients and healthcare providers are turning to these advanced therapies for better outcomes and fewer side effects. Rising Investments in Biopharmaceuticals: The biopharma sector is seeing a surge in funding from pharmaceutical companies, investors, and governments. These investments support research, clinical trials, and manufacturing infrastructure, accelerating the development and availability of biologic drugs. Product Development Collaborations and Agreements: Collaborations between biotech firms and large pharmaceutical companies are common, enabling shared expertise, reduced costs, and faster product development. Licensing deals and joint ventures also help expand market reach and streamline commercialization. Transition Toward Personalized Medicines: Biologics are central to the shift toward personalized medicine, where treatments are tailored to individual genetic profiles. Advances in genomics and diagnostics enable more precise therapies, reducing trial-and-error in treatment. Aging Population and the Prevalence of Chronic Diseases: An aging global population is leading to a higher incidence of chronic diseases such as diabetes, cancer, and arthritis. Biologics offer effective long-term treatment options for these conditions, making them essential in managing the health needs of older adults. Request a sample copy of the global market for biologic therapeutic drugs report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $456.9 billion Market size forecast $794.5 billion Growth rate CAGR of 9.7% for the forecast period of 2024-2029 Segments covered Type, Source, Application, Region Regions covered North America, Europe, Asia-Pacific, Rest of the World(South America and the Middle East and Africa). Countries covered U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy,China, India, Japan, Australia. Market drivers Growing Demand for Biologics Rising Investments in Biopharmaceuticals Product Development Collaborations andAgreements Transition Toward Personalized Medicines Rising Aging Population and the Growing Prevalenceof Chronic Diseases Interesting facts: The biologic therapeutics market is witnessing higher number of approvals for several new therapies and an increase in biologics approvals yearly. In 2023, the market witnessed approvals for breakthrough therapies such as gene editing therapy Casgevy from CRISPR Therapeutics and Vertex Pharmaceuticals and Leqembi (lecanemab) from Eisai for Alzheimer's disease. Emerging startups Arcus Biosciences Allogene Therapeutics Astria Therapeutics Bean Therapeutics HiFiBiO Therapeutics The report addresses the following questions: 1. What is the projected size and growth rate of the market? The global market for biologic therapeutic drugs was valued at $456.9 billion in 2023 and is expected to grow at a CAGR of 9.7% from 2024 to 2029 to reach $794.5 billion by the end of 2029. 2. What factors are driving the growth of the market? The global market for biologics therapeutic drugs is growing due to the world's rising aging population and the growing prevalence of chronic diseases, increasing numbers of product launches, and high demand for personalized medicine. 3. Which market segments are covered in the report? The global market for biologics therapeutic drugs is segmented based on product type, source, application, and region. 4. Which product type segment will be dominant through 2029? The monoclonal antibodies (mAbs) segment will dominate the market through 2029. 5. Which region has the largest market share? North America holds the largest share of the market. Market leaders include: ABBVIE INC. AMGEN INC. ASTRAZENECA BRISTOL-MYERS SQUIBB CO. ELI LILLY AND CO. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. GSK PLC. JOHNSON & JOHNSON SERVICES INC. MERCK & CO. INC. NOVARTIS AG NOVO NORDISK A/S PFIZER INC. REGENERON PHARMACEUTICALS INC. SANOFI Related reports: Antibody Drugs: Technologies and Global Markets: This report provides reviews the global antibody drug market, focusing on monoclonal antibodies (mAbs) used in treating chronic diseases like cancer and autoimmune disorders. It covers market trends, regional analysis, and key companies. Forecasts extend to 2029, highlighting growth in therapeutic applications and technological advances. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Next-Gen Batteries Set for 28.5% CAGR Through 2029
Next-Gen Batteries Set for 28.5% CAGR Through 2029

Yahoo

time8 hours ago

  • Yahoo

Next-Gen Batteries Set for 28.5% CAGR Through 2029

"Comprehensive Market Analysis Highlights Opportunities and Challenges in the Evolving Next-Gen Battery Sector for EVs and Energy Storage" Boston, July 28, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, 'Next-Generation Advanced Batteries: Global Markets' is projected to grow from $1.5 billion in 2024 to $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 28.5% from 2024 through 2029. This report provides a comprehensive analysis of the global market for next-generation advanced batteries, focusing on their applications in various industries. It explores emerging technologies, upcoming trends, the competitive landscape, market dynamics and patent activity. The study also highlights ESG developments and macro-economic factors. It covers four regions: North America, Europe, Asia-Pacific, and the Rest of the World. The report concludes with detailed profiles of leading companies in the industry. This report is especially relevant today as next-generation advanced batteries are rapidly transforming key industries with their superior energy density, longer lifespan, lightweight design, and fast-charging capabilities. These features make them ideal for powering electric vehicles (EV), portable electronics, and grid energy storage systems. Recent advances have also significantly improved safety by reducing the risks of overheating and combustion. With ongoing research driving further gains in performance and reliability, these batteries are becoming increasingly essential for a sustainable energy future. The factors driving the market's growth include: Need for a cost-effective alternative to LIBs: Lithium-ion batteries are expensive due to their use of rare and costly materials. This has created a push for more affordable alternatives that use abundant or recyclable components, making energy storage more accessible and sustainable. Preference for flow batteries over conventional batteries: Flow batteries are gaining popularity, especially for large-scale energy storage, because they offer longer life, better safety, and scalability. Their ability to decouple energy and power capacity makes them ideal for grid applications. Increasing demand for solar energy: As solar power adoption rises globally, there is a growing need for efficient energy storage systems to manage intermittent generation. Advanced batteries help store excess solar energy and ensure a stable power supply. Demand for higher battery energy density: The Ev, aerospace, and consumer electronics industries require batteries that store more energy in smaller, lighter packages. This demand is pushing innovation in next-gen batteries like solid-state and lithium-sulfur technologies. Request a sample copy of the global market for next-generation advanced batteries report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $1.2 billion Market size forecast $5.3 billion Growth rate CAGR of 28.5% from 2024 to 2029 Segments covered Battery Type, End Use, and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (South America, the Middle East and Africa) Market drivers Need for a cost-effective alternative to LIBs. Preference for flow batteries over conventional batteries. Increasing demand for solar energy, facilitating the deployment of next-generation advanced batteries. Demand for higher battery energy density. Interesting facts: According to the International Energy Agency (IEA), global battery manufacturing reached 2.5 terawatt-hours (TWh) in 2023, an increase of 780 gigawatt-hours (GWh) in capacity compared to 2022. This represents a growth of over 25% from the previous year. The IEA reported that EV sales worldwide hit 14 million units in 2023, accounting for 18% of all vehicle sales. This marks a rise from 14% in 2022, with 3.5 million more EVs sold in 2023, a 35% year-on-year increase. The U.S., China, and Europe continued to dominate the next-generation advanced battery market in 2023, collectively accounting for more than 90% of the global market share. Emerging startups Benan Energy Technology (Shanghai) Co., Ltd.: This company researches, develops, and manufactures high-safety SIBs, and is committed to advancing the industrialization of sodium-ion energy storage solutions, which offer safety and environmentally friendly features. QuantumScape Battery, Inc.: QuantumScape, based in San Jose, Calif., develops solid-state rechargeable lithium metal batteries for Evs. Its R&D is focused on two innovations: a codeless architecture and a proprietary solid ceramic separator that improves energy density, charging speeds, and safety. Allegro Energy: The company has developed water-based redox flow batteries to store renewable energy and is looking to build an 800 KWh pilot storage facility in New South Wales, Australia. The report addresses the following questions: What is the market's projected size and growth rate? The global market for next-generation advanced batteries was valued at $1.2 billion in 2023 and is projected to reach $5.3 billion by the end of 2029, with a CAGR of 28.5%. Which factors are driving the growth of the market? Key drivers include: Need for a cost-effective alternative to lithium-ion batteries (LIBs). Preference for flow batteries over conventional batteries. Increasing demand for solar energy facilitating next-generation advanced battery deployment. Demand for higher battery energy density. Which market segments are covered in the report? The next-generation advanced batteries market is segmented based on battery type, end-use, and region. Which battey type segment will be dominant through 2029? Solid state batteries (SSBs) will be the dominant market segment through 2029. Which region has the largest market share? Asia-Pacific holds the largest share of the global market. Market leaders include: BLUE SOLUTIONS S.A.S. CONTEMPORARY AMPEREX TECHNOLOGY CO. LTD. ESS TECH INC. FARADION HINA BATTERY TECHNOLOGY CO. LTD. ILIKA INVINITY ENERGY SYSTEMS LG ENERGY SOLUTION NATRON ENERGY INC. NGK INSULATORS LTD. PANASONIC ENERGY CO. LTD. PRIMUS POWER SOLUTIONS QUANTUMSCAPE BATTERY INC. SK ON CO. LTD. SUMITOMO ELECTRIC INDUSTRIES LTD. Related reports: Global EV Battery Swapping Market: This report reviews the global EV battery swapping market, covering battery types such as lithium-ion, nickel-metal hydride, and lead-acid. It examines manual and automatic swapping stations, service models like subscription and pay-per-use, and applications across passenger cars, commercial vehicles, two-wheelers, and three-wheelers. The report also highlights emerging technologies and developments, competitive dynamics, ESG trends, and the impact of geopolitical events. It includes regional insights and profiles of leading companies, with market values presented in millions of dollars. Flow Batteries: Global Markets: This report provides an analysis of the global flow battery market, focusing on battery types, materials, deployment, and applications, excluding the automotive sector. It explores trends, patent activity, and regional insights, while also addressing the impact of COVID-19 and ESG. The report concludes with profiles of major manufacturers and presents market values in millions of dollars. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store